ERN Rare-Liver on-demand Webinar: The new EASL Clinical Practice Guidelines on sclerosing cholangitis
Description
In this new ERN Rare-Liver webinar, held on 29 November 2022, ERN wanted to draw attention to the new EASL Clinical Practice Guideline on Sclerosing Cholangitis, which has been published in June 2022. Prof. Annika Bergquist, Prof. Christoph Schrammin, Prof. Ulrich Beuers and Prof. Olivier Chazouillères discussed about improving care for patients with PSC and other forms of sclerosing cholangitis.
Targeted Audience
General practitioners
Hepatologists
Oncologists
Health care professionals
Speakers
Dr Annika Bergquist graduated from Karolinska Institutet and completed her postgraduate training at the Karolinska University Hospital, Stockholm. She was appointed as a senior consultant hepatologist in 2007. She received her PhD from the Karolinska Institutet in 2001 with the thesis “Cholangiocarcinoma in PSC” and became adjunct professor at the Karolinska Institutet in 2013. She is leading the research group of PSC studies at Karolinska University Hospital and Karolinska Institutet and is the Chair of the national research network for liver disease (www.swehep.se) and PSC lead in ERN- Rare Liver. The research focus is on clinical studies and biomarkers in PSC.
Christoph Schramm (University Medical Centre, Hamburg-Eppendorf)
Ulrich Beuers is working at the Amsterdam University Medical Centers as Head and Full Professor of Hepatology. Treatment of people with chronic cholestatic and immune-mediated liver diseases are a clinical focus of his work. His group tries to understand the pathogenesis of these diseases and to develop new treatment approaches for affected people.
Olivier CHAZOUILLERES is a French Hepatologist and Head of the Saint-Antoine Hospital Hepatology Department in Paris. He is also head of the French network of rare hepatic diseases and member of RARE LIVER ERN. His research centres of interest are cholestatic and autoimmune liver diseases. He was chairman of the 2022 Clinical Practice Guidelines on sclerosing cholangitis.
